I think that liquid biopsy, that is, using urine or peripheral blood samples will revolutionize cancer care and pathology over time. Right now testing may be more limited with limited clinical trials but over time I think liquid biopsy will not only be used for drug response and monitoring during therapy but also for screening and diagnosis, with less invasive means for appropriate tumor classification. One company in this space that has a proprietary Precision Cancer Monitoring® (PCM) platform is molecular diagnostics company, Trovagene, that empowers healthcare providers and patients to personalize treatment decisions with circulating tumor DNA (ctDNA) as a diagnostic tool. Trovera noninvasive urine-based liquid biopsy tests make it possible to detect cancer mutations and/or monitor changes in tumor dynamics before, during, and after treatment, providing clinically actionable information.
As I mentioned in my post last year after ASCO, I think liquid biopsy will play an important role that will impact pathology and pathologists to help care for oncology patients. I have seen estimates as high as $22 billion as to what this market will be by 2020.
To learn more about this exciting technology, visit Trovagene at Booth 3014 during ASCO 2016!